GB766995A - Improvements in or relating to the production of insulin crystals - Google Patents
Improvements in or relating to the production of insulin crystalsInfo
- Publication number
- GB766995A GB766995A GB30346/54A GB3034654A GB766995A GB 766995 A GB766995 A GB 766995A GB 30346/54 A GB30346/54 A GB 30346/54A GB 3034654 A GB3034654 A GB 3034654A GB 766995 A GB766995 A GB 766995A
- Authority
- GB
- United Kingdom
- Prior art keywords
- insulin
- crystallization
- seed crystals
- size
- crystals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
In the crystallization of insulin from aqueous solution the size of the resulting crystals is controlled by adding a predetermined quantity of insulin seed crystals of a predetermined size. Spontaneous crystallization may be suppressed as far as possible or slight spontaneous crystallization may be allowed.ALSO:A process of crystallizing insulin from an aqueous medium of pH 5 to 7 in the presence of a crystallization-promoting metal e.g. zinc, cobalt, nickel, cadmium, copper, iron, or manganese, comprises seeding the medium with insulin crystals in an amount given by the equation <FORM:0766995/VI/1> where P is the weight in grams of seed crystals used, I is the weight in grams of insulin to be crystallized, and dp and di are the greatest size and the desired upper limit for size in micron of the seed crystals and crystallized insulin respectively. The size of the crystal is defined as the length in micron of the longest diagonal of the crystal. Crystals of uniform size are obtained by preventing spontaneous crystallization e.g. by addition of a buffer substance the anion of which does not bind the crystallization-promoting metal at neutral reaction, and by the use of seed crystals of mainly the same size. Suitable buffers are borate, diethylbarbiturate, maleate or acetate buffers. Crystallization may take place in the presence of halogen in ionic form e.g. as the halide of ammonia, alkali or alkaline earth metals, or mixtures thereof, in a concentration above 0.2 mole per litre, as in Specification 733,740 in which case phosphate or citrate buffers may be used. A basic or acidic solution of insulin which may or may not contain the required content of metals, may be adjusted to the crystallization pH by means of a buffer; the insulin may be precipitated amorphously and subsequently changed into crystalline form by the addition of seed crystals together with the necessary metals, e.g. as an aqueous solution of the metal salt or by the addition of the seed crystals which may themselves exhibit sufficient metal content. The seed crystals may be formed by the process of Specification 766,994 and may be added in the form of an aqueous suspension or in dry freeze dried form. An injectable insulin preparation may be prepared in conjunction with the process of Specification 709,927.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK766995X | 1953-11-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB766995A true GB766995A (en) | 1957-01-30 |
Family
ID=8152702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB30346/54A Expired GB766995A (en) | 1953-11-14 | 1954-10-21 | Improvements in or relating to the production of insulin crystals |
Country Status (2)
Country | Link |
---|---|
CY (1) | CY170A (en) |
GB (1) | GB766995A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000001727A1 (en) * | 1998-06-30 | 2000-01-13 | Novo Nordisk A/S | Seeding crystals for the preparation of peptides or proteins |
US6566490B1 (en) | 1998-06-30 | 2003-05-20 | Novo Nordisk A/S | Seeding crystals for the preparation of peptides or proteins |
US7314859B2 (en) | 2002-12-27 | 2008-01-01 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US7655618B2 (en) | 2002-12-27 | 2010-02-02 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
-
1954
- 1954-10-21 GB GB30346/54A patent/GB766995A/en not_active Expired
-
1958
- 1958-01-02 CY CY17058A patent/CY170A/en unknown
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000001727A1 (en) * | 1998-06-30 | 2000-01-13 | Novo Nordisk A/S | Seeding crystals for the preparation of peptides or proteins |
US6566490B1 (en) | 1998-06-30 | 2003-05-20 | Novo Nordisk A/S | Seeding crystals for the preparation of peptides or proteins |
US7314859B2 (en) | 2002-12-27 | 2008-01-01 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US7642232B2 (en) | 2002-12-27 | 2010-01-05 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US7655618B2 (en) | 2002-12-27 | 2010-02-02 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US7678763B2 (en) | 2002-12-27 | 2010-03-16 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US7678762B2 (en) | 2002-12-27 | 2010-03-16 | Diobex, Inc. | Methods for reducing the risk of hypoglycemia |
US7683027B2 (en) | 2002-12-27 | 2010-03-23 | Diobex, Inc. | Methods relating to hypoglycemic unawareness |
Also Published As
Publication number | Publication date |
---|---|
CY170A (en) | 1958-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB766995A (en) | Improvements in or relating to the production of insulin crystals | |
GB733740A (en) | Improvements in or relating to a process for the production of crystalline insulin | |
US2799622A (en) | Process of producing insulin crystals of substantially uniform size and compositions thereof | |
NO115002B (en) | ||
US2692281A (en) | Preparation of hydrazodicarbonamide | |
GB889769A (en) | Slowly acting insulin preparation in crystalline form | |
GB766994A (en) | Improved process in crystallization of insulin | |
US3669957A (en) | Process for the preparation of sodium ampicillin | |
IL60889A0 (en) | Insulin crystal supsension and process for the preparation thereof | |
GB767629A (en) | Improved process for the preparation of sodium bicarbonate and ammonium sulphate | |
GB757137A (en) | New adrenochrome derivative and process for its production | |
US2286330A (en) | Guanidine ferricyanide complex | |
NO140149B (en) | JOINT HEAT BODY IN PLASTIC. | |
US3020286A (en) | Calcium nicotinate iodide | |
US2704243A (en) | Method of defoliation | |
GB790457A (en) | Improved process for the preparation of sodium chloride | |
US1890453A (en) | Trisodium phosphate-sodium nitrate | |
US4782182A (en) | Method of producing crystals of L-arginine phosphate monohydrate | |
US2512689A (en) | Nicotine compounds containing univalent copper | |
GB1425437A (en) | Crystallization of monosodium citrate | |
GB711246A (en) | Process of producing insulin crystals with increased metal content | |
GB1076981A (en) | Improvements in the manufacture of lead 2:4-dinitroresorcinate | |
GB1390865A (en) | Method of crystallisation | |
GB680653A (en) | Improvements in or relating to production of glutamic acid | |
SU126811A1 (en) | Method for preparing 2-formyl, 4-chlorophenoxy-2 propionic acid and its derivatives |